Polyethylene glycol
/ Polyethylene Glycol 3350 / Potassium / / /, Clenz-lyte, Golytely, Halflytely, Miralax, Mircera, Moviprep, Nulytely, Ocl, Plenvu, Polyethylene Glycol, Polyethylene Glycol 3350 / Potassium / Bicarbonate /, Polyethylene Glycol 3350 / Potassium / Bicarbonate / /, Suclear, Suflave (polyethylene glycol) is a small molecule pharmaceutical. Polyethylene glycol was first approved as Golytely on 1984-07-13. It has been approved in Europe to treat anemia and chronic kidney failure.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Miralax, Polyethylene glycol (discontinued: Glycolax, Polyethylene glycol)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| advance relief eye drops | OTC monograph final | 2019-12-06 |
| advanced relief | C200263 | 2024-12-31 |
| archies dry eye relief | C200263 | 2023-11-15 |
| artificial tears | OTC monograph final | 2019-10-28 |
| assured advanced relief eye | OTC monograph final | 2013-02-28 |
| avenova lubricant eye drops high performance | C200263 | 2023-12-23 |
| basic care clearlax | ANDA | 2023-01-24 |
| berkley and jensen clearlax | ANDA | 2023-05-12 |
| best choice eye drops advanced relief | C200263 | 2023-12-23 |
| blink gel tears | C200263 | 2024-09-20 |
Show 234 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MAGNESIUM SULFATE / POLYETHYLENE GLYCOL 3350 / POTASSIUM CHLORIDE / SODIUM CHLORIDE / SODIUM SULFATE, SUFLAVE, BRAINTREE LABS | |||
| 2026-06-15 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Ascorbic Acid / Polyethylene Glycol 3350 / Potassium Chloride / Sodium Ascorbate / Sodium Chloride / Sodium Sulfate, Plenvu, Salix | |||
| 8999313 | 2033-09-10 | DP | |
| 9326969 | 2033-09-10 | U-2310 | |
| 9707297 | 2033-09-10 | DP | |
| 10016504 | 2033-09-10 | DP | |
| 10918723 | 2033-09-10 | U-2310 | |
| 9592252 | 2032-08-11 | DP | U-2310 |
| 10646512 | 2032-03-25 | DP | |
| 10780112 | 2032-03-09 | DP | |
| 10792306 | 2032-03-09 | DP | U-2310 |
| 11529368 | 2032-03-09 | DP | U-2310 |
| Ascorbic Acid / Polyethylene Glycol 3350 / Potassium Chloride / Sodium Ascorbate / Sodium Chloride / Sodium Sulfate, Moviprep, Salix Pharms | |||
| 7169381 | 2024-09-01 | DS, DP | |
| 7658914 | 2024-09-01 | DS, DP | |
HCPCS
No data
Clinical
Clinical Trials
1403 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 57 | 48 | 50 | 57 | 99 | 297 |
| Hepatitis | D006505 | — | K75.9 | 7 | 27 | 39 | 26 | 47 | 139 |
| Hepatitis c | D006526 | — | B19.2 | 10 | 22 | 36 | 27 | 40 | 130 |
| Hiv | D006678 | — | O98.7 | 11 | 16 | 11 | 25 | 55 | 117 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 5 | 19 | 31 | 22 | 33 | 107 |
| Infections | D007239 | EFO_0000544 | — | 13 | 17 | 20 | 16 | 40 | 103 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | 13 | 50 | 15 | 20 | 98 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 18 | 12 | 17 | 13 | 41 | 97 |
| Colonoscopy | D003113 | — | — | — | 4 | 19 | 22 | 36 | 80 |
| Constipation | D003248 | — | K59.0 | 3 | 10 | 11 | 36 | 18 | 76 |
Show 153 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 9 | 21 | 23 | — | 2 | 49 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 9 | 18 | 21 | — | 2 | 45 |
| Lymphoid leukemia | D007945 | — | C91 | 9 | 18 | 20 | — | 2 | 44 |
| Covid-19 | D000086382 | — | U07.1 | 2 | 6 | 9 | — | 3 | 19 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 5 | — | 5 | 11 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 2 | 3 | 5 | — | — | 9 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 1 | 1 | — | 5 | 9 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | 1 | — | 6 | 9 |
| Hepacivirus | D016174 | — | — | 1 | 1 | 5 | — | 1 | 8 |
| Recurrence | D012008 | — | — | 2 | 4 | 1 | — | 1 | 7 |
Show 78 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | — | — | 10 | 11 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 4 | — | — | 2 | 8 |
| Adenocarcinoma | D000230 | — | — | 3 | 2 | — | — | 4 | 7 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 4 | — | — | 1 | 6 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 3 | — | — | 2 | 5 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | 4 | — | — | 1 | 5 |
| Autism spectrum disorder | D000067877 | — | F84.0 | 1 | 4 | — | — | 1 | 5 |
| Sclerosis | D012598 | — | — | 2 | 2 | — | — | 1 | 4 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 3 | — | — | 1 | 4 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | — | 1 | — | — | 3 | 4 |
Show 83 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 4 | — | — | — | 2 | 6 |
| Pharmacokinetics | D010599 | — | — | 4 | — | — | — | — | 4 |
| Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | 1 | 2 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | 1 | 2 |
| Glioma | D005910 | EFO_0000520 | — | 2 | — | — | — | — | 2 |
| Diverticulitis | D004238 | EFO_1001460 | K57 | 1 | — | — | — | 1 | 2 |
| Warts | D014860 | — | B07 | 1 | — | — | — | 1 | 2 |
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | 2 | — | — | — | — | 2 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | — | — | — | — | 1 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | 1 | — | — | — | — | 1 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Helminthiasis | D006373 | EFO_1001342 | B65-B83 | — | — | — | — | 4 | 4 |
| Disease progression | D018450 | — | — | — | — | — | — | 4 | 4 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 4 | 4 |
| Opportunistic infections | D009894 | — | — | — | — | — | — | 3 | 3 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | — | — | — | 3 | 3 |
| Fecal incontinence | D005242 | — | R15 | — | — | — | — | 3 | 3 |
| Chronic pain | D059350 | — | — | — | — | — | — | 3 | 3 |
| Risk-taking | D012309 | — | — | — | — | — | — | 2 | 2 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | — | 2 | 2 |
| Dermatitis | D003872 | — | L30.9 | — | — | — | — | 2 | 2 |
Show 115 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Polyethylene glycol |
| INN | macrogol |
| Description | Polyethylene glycol (PEG; /ˌpɒliˈɛθəlˌiːn ˈɡlaɪˌkɒl, -ˈɛθɪl-, -ˌkɔːl/) is a polyether compound derived from petroleum with many applications, from industrial manufacturing to medicine. PEG is also known as polyethylene oxide (PEO) or polyoxyethylene (POE), depending on its molecular weight. The structure of PEG is commonly expressed as H−(O−CH2−CH2)n−OH.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 25322-68-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201478 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 11628IH70O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Mircera – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 37,467 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mircera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
63,291 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use